(Press-News.org) Paper Title: Outpatient cervical ripening and labor induction with low-dose vaginal misoprostol reduces the interval to delivery: A systematic review and network meta-analysis
Journal: American Journal of Obstetrics and Gynecology, July 2023
Authors: Joanne L. Stone, MD, MSHCDL, Professor and System Chair of the Raquel and Jaime Gilinski Department of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai; Rachel Meislin, MD, Maternal-Fetal Medicine Fellow at Mount Sinai Hospital; and other coauthors.
Bottom Line: While prior research and analysis have evaluated methods of outpatient labor induction (also known as cervical ripening), the specific approach with the highest efficacy and safety remains uncertain. More than a quarter of all labors in the United States required induction in 2018, according to the National Center for Health Statistics, and will likely continue to rise in the future. This latest study by Mount Sinai researchers aims to identify the most effective and safest cervical ripening strategy. Unlike previous research that were limited to comparing outpatient vs. inpatient inductions or a one-to-one method comparison, this study is among the first to rank a variety of pharmacologic and mechanical labor induction methods used outside a hospital setting, ranging from commonly used prostaglandin medications to alternative supplements and acupuncture.
How: The researchers conducted a systematic review and network meta‐analysis using data from more than 40 randomized, controlled trials with almost 6,100 participants studied in the outpatient setting. The team performed analyses to compare the efficacy of various methods and performed ranking strategies to determine the most effective method. They also assessed the amount of time from labor intervention to delivery, cesarean delivery, need for additional induction methods, a cervix score, Apgar scores (the condition of the newborn immediately after birth), and uterine hyperstimulation, or complications as a result of the induction.
Results: The researchers found that, compared with other available labor induction methods, 25 mcg of the medication misoprostol applied vaginally resulted in the shortest time from medical intervention to delivery. This approach did not increase the likelihood of cesarean delivery, need for additional ripening methods, low Apgar scores, or hyperstimulation. Among the effective methods, the team also found that taking 50 mg of mifepristone by mouth was associated with the lowest risk of cesarean delivery. Acupressure, primrose oil, and castor oil were least effective in reducing the time from labor intervention to delivery and cesarean delivery rates.
Why the Research Is Interesting: This latest research provides additional efficacy and safety data for labor induction methods performed in an outpatient setting—which could potentially reduce patient time in the hospital and enhance hospital efficiency in use of resources and staffing. The data confirms the safety and efficacy of outpatient induction using 25mcg of the medication misoprostol, which is commonly used in the hospital to induce labor. Select patients may be able to start this induction approach at home, requiring less time in the hospital and reducing their medical costs.
Said Mount Sinai's Dr. Rachel Meislin of the research:
"We are excited to add to the growing body of literature regarding the safety of outpatient induction of labor. It is our hope that our findings will contribute to current induction practices."
Researchers from the University of Missouri-Kansas City School of Medicine and University of Florida College of Medicine contributed to this study.
###
View the full paper here. To schedule an interview with the researchers, contact the Mount Sinai Press Office at stacy.anderson@mountsinai.org or 347-346-3390.
END
HOUSTON (Aug. 22, 2023) — The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute® (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatment regimens — specifically for adverse events arising from atherosclerosis.
Cardiovascular disease is the leading cause of death worldwide, with the Centers for Disease Control and Prevention (CDC) estimating that one person dies from CVD every 33 seconds in the United States, accounting for one in every five deaths in 2021.
CVD leads to heart ...
SAN ANTONIO (Aug. 22, 2023) — The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) and seven regional collaborators will leverage $46 million from the National Institutes of Health (NIH) over the next five to seven years to translate scientific discoveries into therapeutic benefits for human health and well-being.
A key focus will be reducing health disparities among Mexican Americans, active military personnel and veterans.
William L. Henrich, ...
The management of working capital — or a firm’s current assets minus its current liabilities — aids organizations in making efficient use of their existing assets and maximizing cash flow.
The relationship between efficient working capital management and firm performance can be complex due to globally dispersed supply chains, number of suppliers and product variety, and technological uncertainty, among other factors.
New research from the University of Notre Dame shows that information technology represents a critical investment that ...
BERLIN, Germany – Stealth BioTherapeutics, a front-runner in the world of mitochondrial medicine, is set to unveil its latest breakthroughs at the much-anticipated Targeting Mitochondria 2023 conference in Berlin this October.
Dr. David A. Brown, Vice President of Mitochondrial Research at Stealth BioTherapeutics, is slated to give an enlightening talk titled, “Translational insights from targeting mitochondria in rare diseases.” His presentation promises to provide insights into Stealth’s progress in clinical programs, with updates on their advancements in addressing rare mitochondrial diseases across several Phase 2/3 clinical trials. ...
Cellular solids are materials composed of many cells that have been packed together, such as a honeycomb. The shape of those cells largely determines the material’s mechanical properties, including its stiffness or strength. Bones, for instance, are filled with a natural material that enables them to be lightweight, but stiff and strong.
Inspired by bones and other cellular solids found in nature, humans have used the same concept ...
A University of Houston researcher is launching a new study to examine how elementary schools across Texas and Florida identify specific learning disabilities in students, with the goal of improving processes so children with significant academic difficulties can succeed.
Jeremy Miciak, research associate professor of psychology at the University of Houston’s Texas Institute for Measurement, Evaluation, and Statistics, was awarded a $1.7 million grant from the National Center for Special Education Research at the Institute of Education Sciences, the research arm ...
“To the best of our knowledge, this is the first study to have demonstrated the preventive effect of AF ablation on long-term AF-related cardiovascular events in very old patients with NVAF.”
BUFFALO, NY- August 22, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 15, entitled, “Cardiovascular events and death after catheter ablation in very old patients with nonvalvular ...
More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the world are searching for new effective substances. Researchers from the University of Bonn, the German Center for Infection Research (DZIF), Utrecht University (Netherlands), Northeastern University in Boston (USA) and the company NovoBiotic Pharmaceuticals in Cambridge (USA) now have discovered and deciphered the mode of action of a new antibiotic. Clovibactin is derived from ...
PHILADELPHIA—(August 22, 2023)—Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio. In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC. In evaluating EBVaGC’s epigenetics — the series of biological signals associated with the genome that determines whether a given gene is expressed — the Tempera lab ...
– By Alison Hatt
The prospect of a quantum internet, connecting quantum computers and capable of highly secure data transmission, is enticing, but making it poses a formidable challenge. Transporting quantum information requires working with individual photons rather than the light sources used in conventional fiber optic networks. To produce and manipulate individual photons, scientists are turning to quantum light emitters, also known as color centers. These atomic-scale defects in semiconductor materials can emit single photons of fixed wavelength or color and allow photons to interact with electron spin properties in controlled ways.
A team ...
